BAM
ADMA icon

Belpointe Asset Management’s ADMA Biologics ADMA Stock Holding History

Belpointe Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,110
Closed -$6.98K – 648
2023
Q1 		$6.98K Buy
2,110
+830
+65% +$2.87K ﹤0.01% 2887
2022
Q4 		$4.97K Buy
+1,280
New +$3.95K ﹤0.01% 2936

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Belpointe Asset Management's ADMA Position: Q2 2023 in Review

Belpointe Asset Management sold out of ADMA Biologics (ADMA) in Q2 2023, closing a stake of 2,110 shares — an estimated $6.98K sold.

Belpointe Asset Management first reported a position in ADMA in Q4 2022 and held it in 2 quarters. The position peaked at $6.98K in Q1 2023. 179 funds tracked by Wall St. Rank hold ADMA as of Q2 2023.

  • Belpointe Asset Management reported no remaining ADMA Biologics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,110 ADMA Biologics shares in Q2 2023, an estimated $6.98K.
  • Belpointe Asset Management first reported a position in ADMA Biologics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's ADMA Biologics position peaked at $6.98K in Q1 2023.
  • 179 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.